According to a recent LinkedIn post from Neuromod Devices Ltd, the company’s Business Development Manager, Cheri Hebeisen, is scheduled to speak at the American Academy of Audiology 2026 conference. The session is described as focusing on Lenire, a tinnitus treatment for which the post cites that 82% of patients report clinically significant relief.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post indicates that Hebeisen will discuss how real-world data may influence treatment outcomes, patient selection, and clinical workflows in tinnitus care. For investors, this visibility at a major professional forum could support clinician awareness, potentially aiding future adoption of Lenire and reinforcing Neuromod’s positioning in the tinnitus and audiology market.
The emphasis on real-world data suggests Neuromod is seeking to differentiate its offering through evidence-based outcomes rather than purely promotional claims. If the cited response rates gain broader clinical acceptance, the company could strengthen its value proposition to hearing care professionals and expand its addressable market over time.